Effects of denosumab on peripheral lymphocyte subpopulations

Endocrine

Volumn 53, Issue 3, 2016, Pages 857-859

  Rossini, Maurizio ^a   Viapiana, Ombretta ^a   Adami, Silvano ^a   Idolazzi, Luca ^a   Ghellere, Francesco ^a   Tripi, Gaia ^a   Ortolani, Riccardo ^b   Zanotti, Roberta ^a   Gatti, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

B LYMPHOCYTE; CELLULITIS; DRUG EFFECT; EAR INFECTION; ENDOCARDITIS; FRAGILITY FRACTURE; GASTROINTESTINAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNE SYSTEM; INFECTION RISK; KIDNEY INFECTION; LETTER; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MONOCYTE; NONHUMAN; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; URINARY TRACT INFECTION; AGED; DRUG EFFECTS; FEMALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 84939605919     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0723-6     Document Type: Letter

References (18)

1. D.L. Lacey, W.J. Boyle, W.S. Simonet, P.J. Kostenuik, W.C. Dougall, J.K. Sullivan, J. San Martin, R. Dansey, Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)
2. N.B. Watts, C. Roux, J.F. Modlin, J.P. Brown, A. Daniels, S. Jackson et al., Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos. Int. 23, 327–337 (2012)
3. S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009)
4. H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, H. Wang, Y. Liu, J. San Martin, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93, 2149–2157 (2008)
5. K.A. Toulis, A.D. Anastasilakis, Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos. Int. 21, 1963–1964 (2010)
6. W.C. Dougall, M. Glaccum, K. Charrier et al., RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412–2424 (1999)
7. Y. Li, G. Toraldo, A. Li et al., B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109, 3839–3848 (2007)
8. S. Ferrari-Lacraz, S. Ferrari, Do RANKL inhibitors (denosumab) affect inflammation and immunity ? Osteoporos. Int. 22, 435–446 (2011)
9. K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42, 52–62 (2012)
10. M.R. Rubin, A.B. Goldfine, D.J. McMahon, D.S. Donovan, S. Cremers, E. Dworakowski, E.J. Schaefer, S.E. Shoelson, S.J. Silverberg, Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine (2015). doi:10.1007/s12020-015-0535-8
11. R. Pacifici, Role of T cells in the modulation of PTH action: physiological and clinical significance. Endocrine 44, 576–582 (2013)
12. S. Lymperi, A. Ersek, F. Ferraro, F. Dazzi, N.J. Horwood, Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 117, 1540–1549 (2011)
13. K. Miyamoto, S. Yoshida, M. Kawasumi, K. Hashimoto, T. Kimura, Y. Sato, T. Kobayashi, Y. Miyauchi, H. Hoshi, R. Iwasaki, H. Miyamoto, W. Hao, H. Morioka, K. Chiba, T. Kobayashi, H. Yasuda, J.M. Penninger, Y. Toyama, T. Suda, T. Miyamoto, Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J. Exp. Med. 208, 2175–2181 (2011)
14. A. Mansour, A. Anginot, S.J. Mancini, C. Schiff, G.F. Carle, A. Wakkach, C. Blin-Wakkach, Osteoclast activity modulates B-cell development in the bone marrow. Cell Res. 21, 1102–1115 (2011)
15. G.B. Rini, D. Sprini, S. Migliaccio, S. Basili, R. Strollo, F. Dieli, N. Napoli, Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates. Endocrine 48, 346–348 (2015)
16. M. Rossini, S. Adami, O. Viapiana, G. Tripi, R. Zanotti, R. Ortolani, A. Vella, S. Troplini, D. Gatti, Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcif. Tissue Int. 93, 249–252 (2013)
17. P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, A.M. DePaoli, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059–1066 (2004)
18. M.R. McClung, E.M. Lewiecki, S.B. Cohen, M.A. Bolognese, G.C. Woodson, A.H. Moffett, M. Peacock, P.D. Miller, S.N. Lederman, C.H. Chesnut, D. Lain, A.J. Kivitz, D.L. Holloway, C. Zhang, M.C. Peterson, P.J. Bekker, Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821–831 (2006)